Importance Among adults with chronic illness, 30% to 50% of medications are not taken as
prescribed. In the United States, it is estimated that medication nonadherence is associated …

Cardiovascular disease is the leading cause of death globally. While pharmacological
advancements have improved the morbidity and mortality associated with cardiovascular …

Background A polypill that includes key medications associated with improved outcomes
(aspirin, angiotensin-converting–enzyme [ACE] inhibitor, and statin) has been proposed as …

A key factor to successful secondary prevention of cardiovascular disease (CVD) is optimal
patient adherence to treatment. However, unsatisfactory rates of adherence to treatment for …

Fixed-dose combination (FDC) therapy, also known as polypill therapy, targets risk factors
for atherosclerotic cardiovascular disease (ASCVD) and has been proposed as a strategy to …

Background Older people taking multiple medications represent a large and growing
proportion of the population. Managing multiple medications can be challenging, and this is …

Background: Adherence to evidence-based cardiovascular (CV) medications after an acute
myocardial infarction (MI) is low after the first 6 months. The use of fixed-dose combinations …

Background Persons with low socioeconomic status and nonwhite persons in the United
States have high rates of cardiovascular disease. The use of combination pills (also called …

Cardiovascular disease (CVD) is the second leading cause of mortality worldwide,
accounting for 17 million deaths in 2013. More than 80% of these cases were in low-and …

Background: Secondary prevention lifestyle and pharmacological treatment of
atherosclerotic cardiovascular disease (ASCVD) reduce a high proportion of recurrent …